- Viral Infections
- Bacterial Infections
- Infektionen bei Immungeschwächten Patienten
- Invasive Pilzinfektionen
-
Gastrointestinale Infektionen
-
Clostridium difficile Infektionen
-
Cadazolid/ ACT-179811 (AC-0641A301)
A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD)
-
CDAD und intestinale Mikrobiota
Multizentrische, prospektive Kohortenstudie zu Mikrobiota-definierten und klinischen Risikofaktoren für eine Kolonisierung mit Clostridium difficile und -assoziierte Erkrankung (CDAD) in Risikokollektiven
-
EXTEND
A phase IIIb/IV randomized, controlled, open label, parallel group study to compare the efficacy of vancomycin therapy to extended duration fidaxomicin therapy in the sustained clinical cure of Clostridium difficile Infection in an older population
-
LCD-CDAD-10-07 (CUBIST)
A Randomized, Double-Blinded, Active-Controlled Study of Surotomycin (CB-183,315) in Patients with Clostridium difficile Associated Diarrhea
-
MODIFY I
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium difficile toxin A), MK-6072 (Human Monoclonal Antibody to Clostridium difficile toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium difficile toxin A and toxin B) in Patients Receiving Antibiotic Therapy for Clostridium difficile Infection (MODIFY I)
-
Cadazolid/ ACT-179811 (AC-0641A301)
-
Clostridium difficile Infektionen